Top

BMC Musculoskeletal Disorders

Published in:

Open Access 01-12-2017 | Research article

Gene expression profiling in patients with polymyalgia rheumatica before and after symptom-abolishing glucocorticoid treatment

Authors: Frederik Flindt Kreiner, Rehannah Borup, Finn Cilius Nielsen, Peter Schjerling, Henrik Galbo

Published in: BMC Musculoskeletal Disorders | Issue 1/2017

Abstract

Background

The pathophysiology, including the impact of gene expression, of polymyalgia rheumatica (PMR) remains elusive. We profiled the gene expression in muscle tissue in PMR patients before and after glucocorticoid treatment.

Methods

Gene expression was measured using Affymetrix Human Genome U133 Plus 2.0 arrays in muscle biopsies from 8 glucocorticoid-naive patients with PMR and 10 controls before and after prednisolone-treatment for 14 days. For 14 genes, quantitative real-time PCR (qRT-PCR, n = 9 in both groups) was used to validate the microarray findings and to further investigate the expression of genes of particular interest.

Results

Prednisolone normalized erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) in PMR patients. A total of 165 putatively clinically relevant, differentially expressed genes were identified (cut-off: fold difference > ±1.2, difference of mean > 30, and p < 0.05); of these, 78 genes differed between patients and controls before treatment, 131 genes responded to treatment in a given direction only in patients, and 44 fulfilled both these criteria. In 43 of the 44 genes, treatment counteracted the initial difference. Functional clustering identified themes of biological function, including regulation of protein biosynthesis, and regulation of transcription and of extracellular matrix processes. Overall, qRT-PCR confirmed the microarray findings: Microarray-detected group differences were confirmed for 9 genes in 17 of 18 comparisons (same magnitude and direction of change); lack of group differences in microarray testing was confirmed for 5 genes in 8 of 10 comparisons. Before treatment, using qRT-PCR, expression of interleukin 6 (IL-6) was found to be 4-fold higher in patients (p < 0.05).

Conclusions

This study identifies genes in muscle, the expression of which may impact the pathophysiology of PMR. Moreover, the study adds further evidence of the importance of IL-6 in the disease. Follow-up studies are needed to establish the exact pathophysiological relevance of the identified genes.

The study was retrospectively listed on the ISRCTN registry with study ID ISRCTN69503018 and date of registration the 26th of July 2017.

Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002;347:261–71. doi:10.1056/NEJMra011913.CrossRefPubMed

Nesher G. Polymyalgia rheumatica - diagnosis and classification. J Aotoimmun. 2014;48-49:76–8.CrossRef

Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet. 2013;381:63–72.CrossRefPubMed

Martinez-Taboada VM, Alvarez L, RuizSoto M, Marin-Vidalled MJ, Lopez-Hoyos M. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine. 2008;44:207–20. doi:10.1016/j.cyto.2008.09.004.CrossRefPubMed

Kreiner F, Langberg H, Galbo H. Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica. Arthritis Rheum. 2010;62:3768–75. doi:10.1002/art.27728.CrossRefPubMed

Healey LA. Polymyalgia rheumatica is the result of synovitis. J Clin Rheumatol. 2006;12:165–6. doi:10.1097/01.rhu.0000230445.14861.fa.CrossRefPubMed

Dasgupta B, Borg F, Hassan N, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology. 2009; doi:10.1093/rheumatology/kep303a.

Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. 2015 recommendations for the management of polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2015;67:2569–80.CrossRefPubMed

Gabriel S, Sunku J, Salvarani C, O'Fallon W, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40:1873–8.CrossRefPubMed

10.

Gonzalez-Gay M, Vazquez-Rodriguez T, Lopez-Diaz M, Miranda-Filloy J, Gonzalez-Juanatey C, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61:1454–61. doi:10.1002/art.24459.CrossRefPubMed

11.

Martínez-Taboda VM, Bartolome MJ, Lopez-Hoyos M, Blanco R, Mata C, et al. HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: influence on clinical subgroups and prognosis. Semin Arthritis Rheum. 2004;34:454–64.CrossRefPubMed

12.

González-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WER. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum. 2003;33:38–48. doi:10.1053/sarh.2002.50025.CrossRefPubMed

13.

Salvarani C, Casali B, Farnetti E, Pipitone N, Nicoli D, et al. Interleukin-6 promoter polymorphism at position −174 in giant cell arteritis. J Rheumatol. 2005;32:2173–7.PubMed

14.

Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, et al. Relationship between interleukin 6 promoter polymorphism at position −174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. J Rheumatol. 2006;33:703–8.PubMed

15.

Kreiner F, Galbo H. Elevated muscle interstitial levels of pain-inducing substances in symptomatic muscles in patients with polymyalgia rheumatica. Pain. 2011;152:1127–32. doi:10.1016/j.pain.2011.01.032.CrossRefPubMed

16.

Chuang TY, Hunder GG, Ilstrup DM, Kurland LT. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med. 1982;97:672–80.CrossRefPubMed

17.

Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71:484–92.CrossRefPubMedPubMedCentral

18.

Bergstrom J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest. 1975;35:609–16.CrossRefPubMed

19.

Borup R, Rossing M, Henao R, Yamamoto Y, Krogdahl A, et al. Molecular signatures of thyroid follicular neoplasia. Endocr Relat Cancer. 2010;17:691–708. doi:10.1677/ERC-09-0288.CrossRefPubMed

20.

Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80. doi:10.1186/gb-2004-5-10-r80.CrossRefPubMedPubMedCentral

21.

Bolstad BM, Irizarry RA, Astrand M. Speed TP A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185–93.CrossRefPubMed

22.

Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279–84.CrossRefPubMed

23.

Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57. doi:10.1038/nprot.2008.211.CrossRef

24.

Hosack DA, Dennis G, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol. 2003;4:R70. doi:10.1186/gb-2003-4-10-r70.CrossRefPubMedPubMedCentral

25.

Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Thera. 2010;12:R176. doi:10.1186/ar3140.CrossRef

26.

Lindsay L, Forbess L, Hatzis C, Spiera R. A prospective open-label phase IIa trial of Tocilizumab in the treatment of polymyalgia rheumatica. Arthritis & Rheumatology. 2016;68:2550–4.CrossRef

27.

Timmons JA, Norrbom J, Schéele C, Thonberg H, Wahlestedt C, et al. Expression profiling following local muscle inactivity in humans provides new perspective on diabetes-related genes. Genomics. 2006;87:165–72. doi:10.1016/j.ygeno.2005.09.007.CrossRefPubMed

28.

Kjaer M. Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol Rev. 2004;84:649–98. doi:10.1152/physrev.00031.2003.CrossRefPubMed

29.

Zuccato C, Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol. 2009;5:311–22. doi:10.1038/nrneurol.2009.54.CrossRefPubMed

30.

Mousavi K, Jasmin BJ. BDNF is expressed in skeletal muscle satellite cells and inhibits myogenic differentiation. J Neurosci. 2006;26:5739–49. doi:10.1523/JNEUROSCI.5398-05.2006.CrossRefPubMed

31.

Aisen P. Transferrin receptor 1. Int J Biochem Cell Biol. 2004;36:2137–43. doi:10.1016/j.biocel.2004.02.007.CrossRefPubMed

32.

Baerlecken NT, Linnemann A, Gross WL, Moosig F, Vazquez-Rodriguez TR, et al. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis. 2012;71:943–7. doi:10.1136/annrheumdis-2011-200413.CrossRefPubMed

33.

Große K, Schmidt R, Witte T, Baerlecken N. Epitope mapping of antibodies against ferritin heavy chain in giant cell arteritis and polymyalgia rheumatica. Scand J Rheumatol. 2013;42:215–9. doi:10.3109/03009742.2012.733959.CrossRefPubMed

34.

Kreiner F, Galbo H. Insulin sensitivity and related cytokines, chemokines, and adipokines in polymyalgia rheumatica. Scand J Rheumatol. 2010;39:402–8. doi:10.3109/03009741003631479.CrossRefPubMed

Title: Gene expression profiling in patients with polymyalgia rheumatica before and after symptom-abolishing glucocorticoid treatment
Authors: Frederik Flindt Kreiner
Rehannah Borup
Finn Cilius Nielsen
Peter Schjerling
Henrik Galbo
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Musculoskeletal Disorders / Issue 1/2017
Electronic ISSN: 1471-2474
DOI: https://doi.org/10.1186/s12891-017-1705-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Gene expression profiling in patients with polymyalgia rheumatica before and after symptom-abolishing glucocorticoid treatment

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Clinical and radiographic predictors of acute compartment syndrome in the treatment of tibial plateau fractures: a retrospective cohort study

Non-vascularised fibula grafts for reconstruction of segmental and hemicortical bone defects following meta- /diaphyseal tumour resection at the extremities

Association of vertebral compression fractures with physical performance measures among community-dwelling Japanese women aged 40 years and older

Accuracy of injection and short-term pain relief following intra-articular corticosteroid injection in knee osteoarthritis – an observational study

Posterior shoulder dislocation with associated reverse Hill-Sachs lesion: treatment options and functional outcome after a 5-year follow up

Large enchondroma of the thoracic spine: a rare case report and review of the literature